- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Solid tumours harbouring neurotrophic receptor tyrosine kinase (NTRK) gene fusions
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 2172KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 488KB)
Larotrectinib – November 2021
Larotrectinib: Capsule 25 mg, Capsule 100 mg, Oral solution 20 mg per mL, 100 mL; Vitrakvi®
Last updated
18 March 2022